$292.82
Value $518B
ABBV and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$292.82
Value $518B
$278.70
Value $672B
AbbVie (ABBV) has a market value of $518B and Johnson & Johnson (JNJ) $672B. Over the last year, with dividends, ABBV moved +29.8% and JNJ +45.4%. The P/E is 50.3 for ABBV and 41.7 for JNJ. Dividend yield: ABBV 2.36%, JNJ 1.89%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ABBV$518B
JNJ$672B
JNJ is 1.3 times ABBV
Revenue, 12 months
ABBV$66.0B
JNJ$99.3B
JNJ is 1.5 times ABBV
Net income, 12 months
ABBV$10.3B
JNJ$16.1B
JNJ is 1.6 times ABBV
Operating margin
ABBV32.2%
JNJ–
ROIC
ABBV25.7%
JNJ12.4%
13.3 points apart
P/E
ABBV50.3
JNJ41.7
ABBV is 1.2 times JNJ
Dividend yield
ABBV2.4%
JNJ1.9%
0.5 points apart
5-year return
ABBV+200.7%
JNJ+97.0%
103.7 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ABBV+200.7%
JNJ+97.0%
| Period | ABBVWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +29.8%Price +26.0% | +45.4%Price +42.2% |
| 3 years since November 17, 2023 | +134.1%+32.8% a yearPrice +111.7% | +102.6%+26.5% a yearPrice +86.1% |
| 5 years since November 16, 2021 | +200.7%+24.6% a yearPrice +151.5% | +97.0%+14.5% a yearPrice +71.3% |
| 10 years since November 17, 2016 | +613.5%+21.7% a yearPrice +374.6% | +213.7%+12.1% a yearPrice +139.1% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ABBVAbbVieJNJJohnson & Johnson
| Price | $292.82 | $278.70 |
|---|---|---|
| Market value | $518B | $672B |
| Enterprise value (EV) | $588B | $699B |
| P/E | 50.3 | 41.7 |
| P/E, 5-year median | 57.0 | 21.9 |
| P/B | – | 8.2 |
| EV/EBIT | 27.7 | 39.4 |
| Free cash flow yield | 3.6% | 3.1% |
| Revenue, 12 months | $66.0B | $99.3B |
|---|---|---|
| Net income, 12 months | $10.3B | $16.1B |
| Free cash flow, 12 months | $18.9B | $20.6B |
| Earnings per share, 12 months | $5.81 | $6.59 |
| Revenue growth, year on year | 8.6% | 6.1% |
| Revenue growth a year, past | +5.9%over 5 years | +2.7%over 5 years |
| EPS growth a year, past | -2.8%over 5 years | +14.9%over 5 years |
| Gross margin | 73.7% | 67.6% |
|---|---|---|
| Operating margin | 32.2% | – |
| Net margin | 15.7% | 16.2% |
| ROIC | 25.7% | 12.4% |
| ROE | – | 19.7% |
| Cash | $10.8B | $17.2B |
|---|---|---|
| Total debt | $80.9B | $44.7B |
| Net debt / EBITDA | 3.2 | 1.1 |
| Interest cover | 7.1× | 18.0× |
| Dividend yield | 2.4% | 1.9% |
|---|---|---|
| Dividend per share, 12 months | $6.92 | $5.28 |
| Dividend growth a year, past | +6.6%over 5 years | +5.3%over 5 years |
| Buyback yield | 0.2% | 0.9% |
| Shareholder yield | 2.6% | 2.8% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($672B) is about 1.3 times AbbVie ($518B), at today's prices.
Since November 17, 2016, ABBV's price moved +374.6% and JNJ's +139.1%. With dividends: ABBV +613.5% (+21.7% a year), JNJ +213.7% (+12.1% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.36% for AbbVie and 1.89% for Johnson & Johnson. Over the last twelve months they paid $6.92 and $5.28 per share.
At today's price, the P/E is 50.3 for ABBV and 41.7 for JNJ. The median of the last five years was 57.0 and 21.9, which shows where each stands against its own past.
Over the last twelve months, the net margin was 15.7% for AbbVie and 16.2% for Johnson & Johnson, and the operating margin 32.2% and –. Revenue was $66.0B and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.